Myriad 'Aggressively' Eyeing M&A, Companion Dx Deals, Euro Opportunities in FY 2011

Myriad officials said the company is focusing on M&A activity, European expansion, and companion diagnostic development in the coming year.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.